Clinical Trial Update: Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 study investigates a quadruplet regimen of venetoclax, dexamethasone, bortezomib, and daratumumab in adolescents and young adults with relapsed or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: T-cell Acute Lymphoblastic Leukemia, Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING